ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotech start-up Algal Scientific has raised $3 million in a financing round led by Evonik Ventures, Formation8 Partners, and Independence Equity. The firm says the funds will allow it to begin commercial-scale production of its algae-derived β-1,3 glucan for use in animal feed, aquaculture, and human nutrition. The polysaccharide, normally made from yeast, is said to have immune-system-supporting benefits. The algae-derived version can be produced at lower cost and is of higher quality, Algal says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X